CD274 and renal cell carcinoma: The molecule CA-170, the first oral small molecule to target PD-L1, demonstrated acceptable safety in a phase I study in Hodgkin lymphoma and solid tumors known to express PD-1, including but not limited to renal cell carcinoma (RCC), melanoma, and non-small cell lung cancer [81,82].